Celator Pharmaceuticals, Inc. Reaches 75 Percent Enrollment Milestone In Phase 3 Study Of CPX-351
6/4/2014 8:58:49 AM
EWING, N.J., June 4, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that it has achieved 75% enrollment in the Company's ongoing Phase 3 clinical study comparing CPX-351 (cytarabine:daunorubicin) Liposome Injection versus the conventional cytarabine and daunorubicin treatment regimen (commonly referred to as 7+3 ) as first-line therapy in older patients with high-risk (secondary) acute myeloid leukemia (AML). The planned enrollment for the study is 300 patients.
Help employers find you! Check out all the jobs and post your resume.
comments powered by